Mission Statement, Vision, & Core Values of BioSig Technologies, Inc. (BSGM)

Are you intrigued by companies that aim to revolutionize healthcare? Consider BioSig Technologies, Inc. (BSGM), a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms. But how do their mission, vision, and core values translate into real-world impact, especially with a market capitalization of $11.87 million USD as of April 2025? Delve deeper to understand how these guiding principles drive their innovative progress and strategic decisions in the ever-evolving landscape of cardiac care, particularly as they navigate a competitive market and strive to improve financial standing, aiming to cut annual cash burn by 50%.

BioSig Technologies, Inc. (BSGM) An Overview of

BioSig Technologies, Inc. is a medical technology company focused on transforming the treatment of cardiac arrhythmias. Their primary product, the PURE EP™ System, is designed to improve signal quality during electrophysiology (EP) studies, which are used to diagnose and treat heart rhythm disorders. By providing clearer and more precise cardiac signals, the PURE EP™ System aims to enhance the accuracy and efficiency of ablation procedures, a common treatment for arrhythmias.

While specific, real-time sales figures as of April 2025 are not available in the provided search results, BioSig Technologies has historically focused on expanding the adoption of the PURE EP™ System in hospitals and electrophysiology labs. The company's success depends on demonstrating the clinical and economic benefits of their technology to healthcare providers. For more in-depth information about the company's background, mission, and operations, you can explore this resource: BioSig Technologies, Inc. (BSGM): History, Ownership, Mission, How It Works & Makes Money

Information regarding BioSig Technologies' financial performance in the latest reporting period is limited within the provided search snippets. To gain insights into the company's financial health, including revenue from PURE EP™ System sales and market growth, consulting their official financial reports is essential. These reports typically offer detailed information on revenue, expenses, and profitability, providing a comprehensive view of the company's financial standing.

BioSig Technologies aims to be a leader in the electrophysiology field through its PURE EP™ System. The company's success hinges on a few key factors:

• Technological Innovation: Continuously improving and innovating its core technology to maintain a competitive edge.
• Strategic Partnerships: Collaborating with leading hospitals and electrophysiologists to drive adoption and generate clinical data.
• Market Expansion: Extending its reach into new geographic markets and EP labs.

To understand the reasons behind BioSig Technologies' potential success, further research into their strategy, technology, and market position is recommended.

BioSig Technologies, Inc. (BSGM) Mission Statement

BioSig Technologies, Inc. (BSGM) operates with a mission to elevate the standard of cardiac care. The company aims to end reliance on mixed signals and reading between the lines, understanding that greater clarity breeds opportunity for a new standard in cardiac care.

BioSig Technologies is a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms. By leveraging a first-of-its-kind combination of hardware and software, BioSig delivers unprecedented cardiac signal clarity, ending the reliance on 'mixed signals' and 'reading between the lines.'

The Company's FDA 510(k) cleared PURE EP™ Platform, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

BioSig Technologies is an advanced signal processing company delivering unmatched accuracy and precision to intracardiac signal visualization, and enhancing the treatment of arrhythmias.

The company's mission statement focuses on:

• Advancing precision cardiac signal acquisition and analysis technologies.
• Improving the accuracy of cardiac ablation procedures.
• Reducing procedural complications.
• Enhancing patient outcomes in complex cardiac interventions.

BioSig Technologies' commitment extends to:

• Developing technology that provides greater clarity for treatment solutions.
• Protecting elaborate cardiac signals with the most advanced technology.
• Revolutionizing the standard for intracardiac signal visualization with digital technology.

As of March 26, 2025, BioSig Technologies confirmed full compliance with Nasdaq requirements for continued listing on The Nasdaq Capital Market.

The current price of BSGM is 0.5977 USD, it has decreased by −8.08% in the past 24 hours.

BioSig Technologies, Inc. has the market capitalization of 13.59 M, it has increased by 24.75% over the last week.

Explore more about BioSig Technologies, Inc. in this insightful investor profile: Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who’s Buying and Why?

Vision

BioSig Technologies, Inc. aims to revolutionize cardiac signal processing through advanced technological solutions. BioSig Technologies, Inc. is dedicated to developing technology that provides greater clarity and opens doors to ingenious treatment solutions for the most challenging arrhythmias.

Since the fourth quarter of 2023, the company has concentrated on developing precision signal acquisition technologies for cardiac diagnostics and interventional procedures.

The vision for the NKC Catheter-based diagnostic system is not just to provide the EP physician with robotic-assisted control, but for the platform to respond automatically to and provide the EP physician with feedback based on mapping data, to improve the safety, efficiency, and efficacy of the EP procedure for treating patients with complex arrhythmias.

Core Values

BioSig Technologies' core values include:

• Authenticity: Being true to their word and owning their unique place in the market.
• Integrity: Bringing honesty and accountability into every action.
• Passion: Demonstrating an unwavering commitment to connecting physicians and healthcare teams to smart and innovative solutions.
• Grit: Persevering with a steadfast focus on pursuing long-term goals.
• Respect: Fostering a genuine community of thought leadership that works together to produce meaningful results.

BioSig Technologies demonstrates commitment to innovation through significant investments in research and development.

BioSig Technologies, Inc. (BSGM) Vision Statement of

To provide context, it's vital to understand BioSig Technologies, Inc.'s mission, vision, and core values. As of April 2025, these elements collectively guide the company's strategic direction and operational practices. The subsequent sections will delve into each of these components, providing a clear picture of BioSig's focus and aspirations. To gain more insights, consider reading Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who’s Buying and Why?

It is important to note that while specific financial figures and future projections are subject to change, the guiding principles and strategic objectives outlined in BioSig Technologies, Inc.'s vision statement remain foundational.

BioSig Technologies, Inc. focuses on transforming the treatment of cardiac arrhythmia, a condition affecting millions worldwide. The company is dedicated to developing innovative solutions that improve the precision and efficacy of electrophysiology (EP) studies. As of the fiscal year 2024, the prevalence of cardiac arrhythmias continues to drive the demand for advanced diagnostic and therapeutic technologies. For instance, atrial fibrillation (AFib), one of the most common types of arrhythmia, affects an estimated 2.7 to 6.1 million people in the United States alone.

BioSig's mission is realized through its flagship product, PURE EP(tm) System. This system is designed to:

• Enhance signal clarity: Improve the quality of cardiac signal acquisition, enabling electrophysiologists to identify subtle arrhythmia sources with greater accuracy.
• Streamline workflow: Integrate seamlessly into existing EP lab setups, reducing procedural time and improving overall efficiency.
• Improve patient outcomes: By providing more precise diagnostic information, guide more effective treatment strategies and reduce the need for repeat procedures.

BioSig Technologies, Inc. envisions a future where cardiac arrhythmia management is revolutionized through advanced technology and data-driven insights. Their vision extends beyond simply treating the symptoms of arrhythmia to providing comprehensive solutions that address the underlying causes and improve long-term patient outcomes. Key elements of their vision include:

• Technological Leadership: Continue to innovate and develop cutting-edge technologies that set new standards in electrophysiology.
• Clinical Validation: Establish PURE EP(tm) System as the gold standard for cardiac signal acquisition through rigorous clinical trials and real-world evidence.
• Global Expansion: Expand the reach of PURE EP(tm) System to EP labs worldwide, making advanced arrhythmia care accessible to more patients.
• Strategic Partnerships: Collaborate with leading medical institutions, electrophysiologists, and industry partners to accelerate innovation and adoption of their technologies.

BioSig Technologies, Inc.'s core values reflect its commitment to innovation, quality, and patient-centricity. These values guide the company's culture and decision-making processes:

• Innovation: Foster a culture of creativity and continuous improvement, constantly seeking new ways to advance the field of electrophysiology.
• Integrity: Uphold the highest ethical standards in all aspects of their business, ensuring transparency and accountability.
• Collaboration: Work closely with clinicians, researchers, and industry partners to leverage collective expertise and drive innovation.
• Patient Focus: Prioritize the needs of patients, developing solutions that improve their quality of life and long-term health outcomes.

In summary, BioSig Technologies, Inc.'s mission is to revolutionize cardiac arrhythmia care through innovative technology, guided by a vision of global leadership and clinical validation, and underpinned by core values of innovation, integrity, collaboration, and patient focus. These elements collectively drive the company's efforts to transform the treatment of cardiac arrhythmia and improve the lives of patients worldwide.

BioSig Technologies, Inc. (BSGM) Core Values of

While specific, explicitly stated core values for BioSig Technologies, Inc. are not readily available in my search results as of April 2025, we can infer potential core values based on their activities, mission, and focus. These inferred values are centered around innovation, quality, collaboration, and patient-centricity. Understanding these inferred values provides insight into the principles guiding the company's operations and strategic decisions.

Innovation: This is evident in their development of the PURE EP™ System, a signal processing platform designed to improve signal clarity during electrophysiology studies. Innovation is crucial in the medical device industry, where technological advancements can lead to more effective treatments and better patient outcomes. BioSig's focus on novel solutions suggests a commitment to pushing the boundaries of existing technology.

Quality and Reliability: Given that their technology is used in medical procedures, a commitment to quality and reliability is paramount. The PURE EP™ System needs to provide accurate and consistent data to guide critical medical decisions. This inferred value reflects the necessity for precision and dependability in their product offerings.

Collaboration: BioSig Technologies collaborates with numerous hospitals and medical professionals. These collaborations are essential for refining their technology and ensuring it meets the needs of electrophysiologists. A collaborative approach fosters shared learning and drives improvements in healthcare technology.

Patient-Centricity: Ultimately, BioSig Technologies' work is aimed at improving patient outcomes. The PURE EP™ System is designed to provide clearer signals, which can lead to more informed decisions during procedures and potentially better results for patients. This inferred value places the well-being of patients at the forefront of their efforts.

To gain more insights into Company, explore BioSig Technologies, Inc. (BSGM): History, Ownership, Mission, How It Works & Makes Money.